SIGA — what changed in the latest 10-Q
A section-by-section comparison of SIGA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-06 vs the prior 10-Q · 2026-05-07
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +11 | −5 | ~19 | 19 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~3 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-06
Cost of sales and supportive services for the three months ended June 30, 2026 and 2025 were $17.6 million and $25.6 million, respectively. Such costs in 2026 were primarily associated with costs for the manufacture and delivery of courses of IV TPOXX® to the U.S. Government under the 19C BARDA Cont…
Research and development (“R&D”) expenses for the three months ended June 30, 2026 and 2025 were $4.4 million for both periods. While the total R&D expenses remained relatively flat, we incurred increased direct vendor related costs associated with the 19C BARDA Contract, as well as increased consul…
For the six months ended June 30, 2026, revenues from product sales and supportive services were $41.4 million. Such revenues include $25.6 million of IV TPOXX® sales to the U.S. Government under the 19C BARDA Contract, $13.0 million of sales to two international countries, as well as $2.8 million o…
Revenues from research and development activities for the six months ended June 30, 2026 and 2025, were $5.8 million and $3.2 million, respectively. The revenues for the six months ended June 30, 2026, were earned in connection with performance of research and development activities under the 19C BA…
Cost of sales and supportive services for the six months ended June 30, 2026 and 2025 were $20.5 million and $25.7 million, respectively. Such costs in 2026 were primarily associated with the costs for the manufacture and delivery of courses of IV TPOXX® to the U.S. Government under the 19C BARDA Co…
Text removed vs the prior filing · source: 10-Q · 2026-05-07
Cost of sales and supportive services for the three months ended March 31, 2026 and 2025 were $2.9 million and $0.2 million, respectively. Such costs in 2026 were primarily associated with the costs of supportive services in connection with a manufacturing technology transfer, as well as costs for t…
Research and development (“R&D”) expenses for the three months ended March 31, 2026 and 2025 were $3.9 million and $3.5 million, respectively, reflecting an increase of approximately $0.4 million. The expense increase is primarily attributable to costs incurred in connection with the EMA referral pr…
As of March 31, 2026, we had $145.6 million in cash and cash equivalents, compared with $155.0 million at December 31, 2025. We believe that our liquidity and capital resources will be sufficient to meet our anticipated requirements for at least the next twelve months from the issuance of these fina…
Cash used in financing activities for the three months ended March 31, 2026 was $0.7 million, which was attributable to the payments of tax obligations in connection with stock issued to employees as well as payments of accrued dividends on vested equity awards. Cash used in financing activities for…
On March 26, 2026, the Board of Directors declared a special cash dividend of $0.60 per share on the common stock of the Company. The special cash dividend was paid on April 23, 2026, to shareholders of record at the close of business on April 7, 2026.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice